Janux Therapeutics (JANX) Competitors $36.01 -1.16 (-3.12%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$36.51 +0.50 (+1.37%) As of 02/21/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends JANX vs. RVMD, LEGN, BBIO, AXSM, BPMC, TLX, ELAN, LNTH, NUVL, and CYTKShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Revolution Medicines Legend Biotech BridgeBio Pharma Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Lantheus Nuvalent Cytokinetics Janux Therapeutics (NASDAQ:JANX) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and community ranking. Does the media prefer JANX or RVMD? In the previous week, Revolution Medicines had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 4 mentions for Revolution Medicines and 0 mentions for Janux Therapeutics. Revolution Medicines' average media sentiment score of 0.73 beat Janux Therapeutics' score of 0.00 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Overall Sentiment Janux Therapeutics Neutral Revolution Medicines Positive Does the MarketBeat Community favor JANX or RVMD? Revolution Medicines received 49 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 75.83% of users gave Revolution Medicines an outperform vote while only 71.19% of users gave Janux Therapeutics an outperform vote. CompanyUnderperformOutperformJanux TherapeuticsOutperform Votes4271.19% Underperform Votes1728.81% Revolution MedicinesOutperform Votes9175.83% Underperform Votes2924.17% Is JANX or RVMD more profitable? Revolution Medicines has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Janux Therapeutics-463.91% -10.47% -9.86% Revolution Medicines N/A -33.67%-30.08% Which has stronger earnings & valuation, JANX or RVMD? Janux Therapeutics has higher earnings, but lower revenue than Revolution Medicines. Janux Therapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$8.08M233.89-$58.29M-$1.17-30.78Revolution Medicines$11.58M600.54-$436.37M-$3.59-11.52 Which has more volatility & risk, JANX or RVMD? Janux Therapeutics has a beta of 3.16, suggesting that its stock price is 216% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Do analysts prefer JANX or RVMD? Janux Therapeutics currently has a consensus target price of $89.90, suggesting a potential upside of 149.65%. Revolution Medicines has a consensus target price of $66.25, suggesting a potential upside of 60.26%. Given Janux Therapeutics' higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Do insiders and institutionals hold more shares of JANX or RVMD? 75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 29.4% of Janux Therapeutics shares are held by company insiders. Comparatively, 8.0% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryRevolution Medicines beats Janux Therapeutics on 11 of the 19 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.89B$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-30.786.1326.4618.82Price / Sales233.89313.76455.0280.40Price / CashN/A67.8344.0437.47Price / Book4.836.747.634.64Net Income-$58.29M$138.11M$3.18B$245.69M7 Day Performance-0.99%-2.43%-1.91%-2.66%1 Month Performance-10.38%-1.91%-0.19%-2.15%1 Year Performance146.48%-5.03%16.70%12.90% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics3.1282 of 5 stars$36.01-3.1%$89.90+149.7%+174.0%$1.89B$8.08M-30.7830RVMDRevolution Medicines4.5103 of 5 stars$40.67-1.6%$66.25+62.9%+41.7%$6.84B$11.58M-11.33250LEGNLegend Biotech2.594 of 5 stars$36.42+0.1%$79.50+118.3%-33.7%$6.65B$285.14M-38.341,800News CoveragePositive NewsGap UpBBIOBridgeBio Pharma4.7169 of 5 stars$34.90+10.6%$49.08+40.6%+7.9%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5246 of 5 stars$131.15-0.4%$147.13+12.2%+67.8%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines2.9952 of 5 stars$93.94-1.3%$123.83+31.8%+5.7%$5.97B$249.38M-44.52640Earnings ReportTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.0515 of 5 stars$11.26-3.4%$16.29+44.7%-31.9%$5.57B$4.42B28.159,300Analyst ForecastLNTHLantheus4.5798 of 5 stars$79.94-2.5%$131.86+64.9%+37.9%$5.56B$1.30B13.30700Analyst RevisionNews CoveragePositive NewsNUVLNuvalent2.1211 of 5 stars$77.93-3.7%$112.36+44.2%-3.7%$5.54BN/A-22.4640Upcoming EarningsInsider TradeCYTKCytokinetics4.1875 of 5 stars$46.16+10.9%$82.00+77.6%-34.3%$5.45B$7.53M-8.58250High Trading Volume Related Companies and Tools Related Companies RVMD Competitors LEGN Competitors BBIO Competitors AXSM Competitors BPMC Competitors TLX Competitors ELAN Competitors LNTH Competitors NUVL Competitors CYTK Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:JANX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
